HAVE YOU BEEN AFFECTED BY THE DRUG TASIGNA?
You may be eligible for the Tasigna class action lawsuit!
The Tasigna lawsuit being filed against Novartis focus on a specific number of serious complications that have been identified through medical studies of the drug. The U.S. Food and Drug Administration (FDA) has required black box warnings for some of these side effects, including the risk of sudden death and QT prolongation.
WE CONNECT YOU TO THE BEST MEDICAL MALPRACTICE LAW FIRMS
Unfortunately, often times the result of corporate and pharmaceutical negligence can have a large impact on your physical and financial livelihood. If this is the case it is important that you speak with an attorney regarding your options. Fill out the form below and one of our staff will reach out to you to schedule a FREE consultation to help educate and navigate you to find the best medical malpractice lawyers near you.
SEVERE TASIGNA SIDE EFFECTS
Some of the dangerous Tasigna side effects referenced in lawsuit claims include:
Sudden Death
One of the most frightening complications that can occur in patients who take Tasigna is sudden death. Although some researchers suspect that heart rhythm problems played a role in these deaths, there is no way to reliably predict who is at risk.
Long QT Syndrome
The QT interval is a measurement of the heart's electrical cycle. Tasigna has been shown in studies to extend the QT interval in some people, which can lead to a type of irregular heartbeat known as torsade de pointes. This is a serious condition that can result in syncope (fainting), seizure, or even death.
Birth Defects
Some studies have shown an increased risk of harm to fetuses in pregnant women who take Tasigna.
Tasigna Drug Interactions
Tasigna can cause problems if taken with certain drugs, including CYP3A inhibitors (including some HIV drugs), CYP3A inducers, and drugs that regulate the heart rhythm.
Cardiovascular Events
Problems related to the heart and blood vessels are among the most common severe side effects of Tasigna, primarily due to atherosclerosis-related conditions. These problems include ischemic heart disease-related cardiac events (heart attacks), ischemic cerebrovascular events (strokes), peripheral artery disease and blocked arteries in the arms, legs, or extremities.
Bleeding
Severe bleeding potentially leading to death may occur in CML patients who take Tasigna. Individuals who take an anticoagulant such as Pradaxa or Xarelto may need to be especially careful.
Tasigna can also cause problems for some people who have or have had certain medical conditions, including lactose intolerance, pancreatitis, or a total gastrectomy.
FDA Warning About Tasigna Marketing on Facebook
In 2010, the FDA sent a warning letter to Novartis Pharmaceuticals that the company's advertising efforts on Facebook violated the agency's guidance on the use of social media for marketing drugs. It was the first warning letter of its kind sent by the FDA.
The FDA highlighted several problems with Tasigna's Facebook ads
Risks: The ads did not adequately inform readers of the risks of taking Tasigna, including the black box warnings included on the warning labels.
Indications: The ads incorrectly implied that Tasigna could treat all forms of CML, rather than a subset of people with the disease.
Effectiveness: The ads used terms like "next-generation" in describing Tasigna, suggesting that it was more effective than similar drugs, but the FDA said such claims are unsubstantiated.
Health Canada Tasigna Warning
Problems with Tasigna have also been identified by Health Canada, the Canadian government's agency charged with overseeing the health and safety of Canadian citizens. Specifically, in 2013, Health Canada issued an alert related to Tasigna and the possible development of atherosclerosis in those who have taken the drug. The alert indicated that Novartis had reported at least 277 cases of atherosclerosis in people who took Tasigna, based on clinical trial data collected between 2005 and 2013.